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Abstract: 
Aim: To undertake a systematic review and meta-analysis of randomized controlled trials of the effect of 
Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) therapy on serum C-reactive protein (CRP) 
concentrations. 
Method: PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched for the 
period up until March 16 2016. Prospective studies evaluating the impact of GLP-1 RAs on serum CRP were 
identified. A random effects model (using the DerSimonian-Laird method) and generic inverse variance 
methods were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out 
method. Heterogeneity was quantitatively assessed using the I
2
 index. Random effects meta-regression was 
performed using unrestricted maximum likelihood method to evaluate the impact of potential moderator.  
International Prospective Register for Systematic Reviews (PROSPERO) number CRD42016036868. 
Results: Meta-analysis of the data from 7 treatment arms revealed a significant reduction in serum CRP 
concentrations following treatment with GLP-1 RAs (WMD –2.14 (mg/dL), 95% CI -3.51, –0.78, P=0.002; I2 
96.1%). Removal of one study in the meta-analysis did not change the result in the sensitivity analysis (WMD –
2.14(mg/dL), 95% CI -3.51, –0.78, P=0.002; I2 96.1%), indicating that our results could not be solely attributed 
to the effect of a single study. Random effects meta-regression was performed to evaluate the impact of 
potential moderator on the estimated effect size. Changes in serum CRP concentration were associated with 
the duration of treatment (slope –0.097, 95% CI –0.158, -0.042, P<0.001).  
 
Conclusions: This meta-analysis suggests that GLP-1 RAs therapy causes a significant reduction in CRP. 
 
Keywords: meta-analysis, Glucagon-like peptide-1 receptor agonist, C-reactive protein. 
Word count: 233 
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Introduction: 
Obesity and T2DM are both associated with an increased risk of cardiovascular disease (CVD) These conditions 
are also now recognised as having an inflammatory component [1]. A number of cytokines and inflammatory 
signalling pathways have been shown to be involved in the development of CVD, as indicated by increased 
serum levels of several inflammatory biomarkers, including: tumour necrosis factor-a (TNF-a), C reactive 
protein (CRP), high molecular weight adiponectin (HMW-adiponectin), and interleukin (IL)-6 [2]. The potential 
role of inflammation in the complications of obesity is offering further insight into the relationship between 
T2DM and CVD has led to a greater interest on specific therapeutic targeting. Glucagon-like peptide-1 (GLP-1) 
is a gut hormone, secreted from the intestine in response to meal ingestion, which stimulates insulin secretion 
and inhibits glucagon release in a dose-dependent fashion [3]. GLP-1 can suppress appetite, food intake,  
decelerate gastric emptying and induce satiety, so it plays an important role in the regulation of blood glucose 
[4, 5]. GLP-1 receptor agonists (GLP-1 RAs) include exenatide, liraglutide, albiglutide, taspoglutide, lixisenatide. 
Treatment with GLP-1 RAs improve insulin resistance and glucose homoeostasis in patients with Type 2 DM [6, 
7]. The use of these agents, also have a low risk of hypoglycemia because of their mode of action. Exenatide 
and liraglutide are currently successfully being employed in the treatment of Type 2 DM [8]. However, the data 
on the effect of GLP-1 RAs on serum CRP is inconsistent. Hence the aim of this study was to assess the 
reported effects of GLP-1 RAs on serum CRP by systematically reviewing the existing randomize control trials. 
 
Methods 
Literature search strategy 
A systematic review was undertaken according to the international referred Reporting Items for Systematic 
Reviews and Meta- Analyses (PRISMA) Guidelines [9, 10]. The primary exposure of interest was GLP-1 RAs use 
and the primary outcome was the change in CRP concentration status subsequent to GLP-1 RAs use. The 
secondary aim of this study was to assess the effect of duration of GLP-1 RAs therapy on serum CRP 
concentrations. We searched multiple databases including PUBMED, Medline, Cochrane Central Register of 
Controlled Trials (CCTR), Cochrane Database of Systematic Reviews (CDSR), Web of Science, Gray Literature 
sources, SCOPUS, and clinicaltrial.gov registry until March 2016, for both published and unpublished studies on 
changes in serum CRP concentration in relation to treatment with GLP-1 RAs. We used a combination of 
relevant search terms (Supplementary Table 1). No language restriction was applied. Additionally, we hand-
searched the reference list of eligible articles and contacted authors for missing information/clarifications 
where relevant. Results of unpublished trials were retrieved, if available, from www.clinicaltrials.gov, or 
www.clinicalstudyresults.org, as well as Food and Drug Administration and European Medicines Agency 
(EMEA, www.ema.europa.eu) reviews of approved drugs. All those sources were also used to complete 
information on results of published trials, when not reported in publications (including the primary trial 
publications, and subsequent reviews and/or pooled analyses reporting data on individual trials). The full text 
of studies meeting the inclusion criteria retrieved and screens to determine eligibility by two reviewers (MM, 
EE). Disagreements resolved through discussions between reviewers until consensus reached. International 
Prospective Register for Systematic Reviews (PROSPERO) number CRD42016036868. 
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 Selection criteria 
We included prospective studies evaluating the effect of GLP-1 RAs use on serum CRP levels. Eligible studies 
had to meet following criteria: (1) a controlled trial with either parallel or crossover design; (2) presentation of 
sufficient information on CRP concentrations at baseline and at the end of follow-up in each group or providing 
the mean change during follow-up. Unclear studies, poorly described and only abstract papers were excluded. 
Narrative reviews, comments, opinion pieces, methodological, editorials, letters or any other publications 
lacking primary data and/or explicit method descriptions, were also excluded. After removal of duplicates, two 
investigators (MM & EE) independently screened studies by title, abstract and full text as appropriate for 
inclusion. The agreement between the two investigators was excellent (Kappa index: 0.91; p<0.001)). 
Disagreements were resolved at a meeting between reviewers prior to selected articles being retrieved (a flow 
chart is available in supplementary Figure 1). For multiple publications from the same study, only the most 
complete reports were included. 
Data extraction and management: 
Two reviewers entered data onto a purpose-designed data extraction form and independently summarised 
what they considered to be the most important results from each study. These summaries compared any 
differences of opinion resolved by discussion and consultation with a third reviewer. Any further calculations 
on study data considered necessary was conducted by the first reviewer and checked by the second reviewer. 
The quality of trials was assessed using some of the parameters proposed by Jadad et al, [11]First author, year, 
differential interventions in study groups, duration of interventions (week), sample size, number of men (%), 
mean age and trials quality were summarized in table 1. 
Quality Assessment: 
A systematic assessment of bias in the included RCTs was performed using the Cochrane criteria [12]. The 
items used for the assessment of each study were the following: adequacy of random sequence generation, 
allocation concealment, blinding of participants, personnel and outcome assessment, handling of drop-outs 
(incomplete outcome data), selective outcome reporting, and other potential sources of bias. According to the 
reĐoŵŵeŶdatioŶs of the CoĐhraŶe HaŶdďook, a judgŵeŶt of ͚yes͛ iŶdiĐated loǁ risk of ďias, ǁhile ͚Ŷo͛ 
iŶdiĐated high risk of ďias. LaďelliŶg aŶ iteŵ as ͚uŶĐlear͛ iŶdiĐated aŶ uŶĐlear or uŶkŶoǁŶ risk of bias. 
 
Quantitative data synthesis: 
A random effects model (using the DerSimonian– Laird method) and the generic inverse variance method were 
used to compensate for the heterogeneity of studies in terms of demographic characteristics of populations 
being studied and also differences in study design and type of statin being studied [13]. Heterogeneity was 
quantitatively assessed using the I
2
 index. Effect sizes were expressed as weighted mean difference (WMD) 
and 95% confidence interval (CI). In order to evaluate the influence of each study on the overall effect size, 
sensitivity analysis was conducted using the leave-one-out method, i.e. removing one study each time and 
repeating the analysis [14-16]. When the outcome measure was reported as median and range (or 95% 
confidence interval [CI]), mean and standard deviation (SD) values were estimated using the method described 
by Hozo et al. [17]. Where standard error of the mean (SEM) was only reported, the SD was estimated using 
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the following formula: SD = SEM × square root (n), where n is the number of subjects. If the outcome measures 
were reported in median and 25
th
-75
th
 percentiles (P25-P75), mean and standard SD values were estimated 
using a method previously defined [17]. To convert P25-P75 into a minimum–maximum range, the following 
equations were used: maximum = median + 2 *(P75-median) and minimum = median - 2 * (median-P25), 
where P25, and P75 are the 25
th
 and 75
th 
percentiles, respectively. All values were collated in percentage of 
change. SDs of the mean difference were estimated using the following formula: SD = square root 
[(SDpretreatment)
2
 + (SDposttreatment)
2
 _ (2R * SDpretreatment * SDposttreatment)]. Because the pretest–posttest correlation 
coefficients (r) were not reported in studies, an r value of 0.5 was assumed through this meta-analysis, as this 
value was a conservative estimate for r which ranges between 0 and 1 [18]. In order to check if the r value 
could alter the results of the meta-analysis, sensitivity analyses were performed by repeating the analysis with 
r values of 0.2, 0.3, 0.7 and 0.8. The results showed the robustness of the pooled estimate with different r 
values. 
Meta-regression  
Random effects meta-regression was performed using the unrestricted maximum likelihood method to 
evaluate the association between calculated WMD and potential moderator, duration of treatment with GLP-1 
RAs. 
Publication bias 
Potential publication bias was explored using visual inspection of Begg͛s funnel plot asymmetry, Begg͛s rank 
correlation and Egger͛s weighted regression tests. Duval & Tweedie ͚trim and fill͛ and ͚fail-safe N͛ methods 
were used to adjust the analysis for the effects of publication bias[19]. Meta-analysis was conducted using 
Comprehensive Meta-Analysis (CMA) V3 software (Biostat, NJ)[20]. 
 
Results 
Summary of searches and study selection process 
The search strategy identified 532 citations. Three hundred and ninety records remained after removing 
duplicates. After initial screening based on titles and abstracts, 43 articles remained for further evaluation. 36 
full- text articles were excluded for the following reasons: 1- They were non-human studies, genetic, or 
molecular studies (n=30); 2- They were reviews or editorial articles (n=6). Study selection with flow diagram 
based on the PRISMA guidelines shown in supplementary figure 1. 
Characteristics of the included studies 
The remaining 7 studies met our inclusion criteria and were included in the meta-analysis. Two of these studies 
were prospective cohort studies and the others are randomized clinical trials. Publication years were between 
2010 and 2014, and the duration of the studies ranged from 8 weeks to 52 weeks. 2 trials compared GLP-1 
agonist (exenatide) with metformin on non-diabetic individuals with abdominal obesity and either IFG, 
elevated HbA1c or IGT [21] and withT2DM and concomitant non-alcoholic fatty liver disease (NAFLD) [22], 
respectively. One trial compared GLP-1 agonist (exenatide) with placebo on a background of basal insulin with 
oral anti-diabetic drugs [23]. One study compared GLP-1 agonist (exenatide) with glibenclamide on patients 
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with uncontrolled type 2 diabetes mellitus receiving therapy with metformin [24]. One trial compared GLP-1 
agonist (exenatide) with insulin glargine on metformin-treated patients with type 2 diabetes [25]. One study 
compared GLP-1 agonist (liraglutide) versus placebo on glucose-tolerant patients with plaque psoriasis [26]. At 
the end, one trial investigated effect of exenatide therapy in obese people with type 2 diabetes mellitus 
(T2DM) and hypertension after laparoscopic Roux-en-Y gastric bypass (RYGB) surgery [27].  
Participants in two studies were only female, while the proportion of men in other studies ranged from 24% 
[21] to 65% [27].  Studies were from countries including the Denmark (one study), United States of America 
(one study), Italy (one study), China (three study) and Netherlands (one study). The number of participants 
included in studies ranged from 20 [26] to 117 [22]. The range of age participants was from 18 years [24] to 69 
years [21]. Moreover, each of these studies had its own inclusion criteria which are listed in Table 1. 
Risk of Bias Assessment 
There is unclear risk of bias in some of items including allocation concealment, blinding of participants and 
personnel. All of the studies had a low risk of bias according to selective outcome reporting. Details of the 
quality of bias assessment are shown in supplementary table 2. 
Pooled estimate of GLP-1 RAs treatment on CRP 
The pooled estimate (weighted mean difference) of the effect of GLP-1 RAs treatment on CRP levels was 
(WMD –2.14 (mg/dL), 95% CI -3.51, –0.78, N=7 studies, heterogeneity P=0.002; I2 96.1%) across all studies. 
 
Sensitivity analysis 
In leave-one-out sensitivity analyses, the pooled effect estimates remained similar across all studies (WMD –
2.14 (mg/dL), 95% CI -3.51, –0.78, N=7 studies, heterogeneity P=0.002; I2 96.1%), fig 1. 
Meta-regression: 
Random effects meta-regression was performed to evaluate the impact of potential moderator on the 
estimated effect size. Changes in serum CRP concentration were associated with the duration of treatment 
(slope –0.097, 95% CI –0.158, -0.042, P<0.001) (Figure 2). 
Pooled estimate of GLP-1 RAs treatment on plasma adiponectin:    
Meta-analysis of the data from 3 treatment arms revealed a significant change in plasma adiponectin 
concentration following treatment with GLP-1 RAs (WMD 0.64, 95% CI 0.38, 0.89, P<0.001; I
2
 46%). This effect 
was robust in the sensitivity analysis (Figure 3). 
Publication bias 
The funnel plot of standard error vs. effect size (mean difference) was asymmetric and suggested potential 
publication bias, fig4. Moreover, the presence of publication bias was suggested by Egger͛s linear regression 
(intercept = -10.6, standard error = 5.47; 95% CI = -24.7, 3.42, t = 1.96, df = 5.00, two-tailed P = 0.109). 
Hoǁeǀer, Begg͛s raŶk ĐorrelatioŶ test (KeŶdall͛s Tau with continuity correction =-0.50, z = 1.65, two tailed P 
value =0.098) did not indicate significant publication bias. After adjustment of effect size for potential 
publication bias using the ͚trim and fill͛ correction, no potentially missing studies were imputed in the funnel 
plot, hence no difference on effect size than the initial estimate (WMD –0.99, 95% CI -1.22, –0.76) (Figure 3). 
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The ͚fail-safe N͛ test showed that 243 studies would be needed to bring the WMD down to a non- significant (P 
> 0.05) value. 
 
Discussion 
 The GLP-1 RAs are a novel class of glucose-lowering drugs which have been shown to improve glycaemic 
control and promote weight loss in clinical studies of patients with Type 2DM and obesity. Nevertheless, little 
is known about the effects of chronic treatment with GLP-1 receptor agonist on inflammatory markers that are 
known to be associated with obesity or type 2 diabetes. We have reviewed studies that have investigated the 
effects of GLP-1 receptor agonist on the inflammatory biomarker CRP. Meta-analysis revealed that these 
agonists have a potentially beneficial effect on serum CRP concentrations, as we observed a significant 
reduction in serum CRP concentration following treatment with GLP-1 RAs. The GLP-1 RAs used for most of 
these studies was exenatide, which is a synthetic analogue of exendin-4, a 39-amino-acid agonist of GLP-1 
receptor. It can promote glucose-dependent insulin secretion, inhibit inappropriate secretion of glicentin, 
delay gastric emptying, and suppress appetite to reduce blood glucose and body weight [31]. in a recent study 
investigating the effects of three different dose of liraglutide (0.6 mg, 1.2 mg and 1.8 mg) in patients with type 
1 diabetes mellitus; serum CRP concentrations fell significantly by 15 ± 6% (from 3.01± 0.92 to2.53 ± 0.83 g/L, P 
< 0.05) in the liraglutide 1.2-mg group and by 19±8% (from 3.53±0.67 to 2.57±0.52 g/L, P < 0.05) in liraglutide 
1.8 mg group [32]. Furthermore, Bunck et al showed that exenatide was superior to insulin glargine in 
improving the risk factors of cardiovascular diseases such as adiponectin and CRP [25]. It has been shown that 
there is a highly significant association between elevated CRP and glucose control in T2DM [33]. We also 
reviewed the effect of GLP-1 RAs on serum adiponectin in these studies. Adiponectin is another inflammatory 
marker, derived from adipose tissue that has been shown to be involved in the obesity and T2DM complicated 
by cardiovascular diseases. Three studies in this systematic review also evaluated serum adiponectin 
concentration after treatment with GLP-1 RAs agonist in patients [22, 25, 27]. They reported GLP-1 RAs had a 
significant effect on increasing serum adiponectin concentrations. Our analysis also revealed a significant 
change in plasma adiponectin concentrations following treatment with GLP-1 RAs. TNF-a is a major negative 
regulator that can block fatty acid oxidation and glucose uptake and induce metabolic disorders [34]. It 
hypothesized, adiponectin with its antagonistic effects on TNF-a, may improve diabetes, hypertension, 
apoptosis, and atherosclerosis [35]. The Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular 
outcome Results (LEADER) trial showed conclusive data regarding the cardiovascular safety of liraglutide 
relative to standard of care for a global population of patients with T2DM[36]. 
In conclusion, GLP-1 RAs, appear to reduce serum CRP and increase serum adiponectin concentrations and 
may therefore attenuate the inflammatory state, and hence reduce the risk of CVD, and the degree of insulin 
resistance in patients with diabetes. Furthermore, the reduction in inflammatory markers such as CRP may 
also indicate that these agents reduce the risk of diabetic complications, including nephropathy and 
atherosclerosis. 
Limitation: 
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Although we believe that the present meta-analysis provides useful information, there are some potential 
limitations that need to be addressed. First, as with any meta-analysis, internal validity relies on the quality of 
individual studies. Several limitations of this meta-analysis should be noted. Firstly, the majority of the  studies 
finally included in the analysis had relatively small sample sizes, potentially leading to publication bias and 
overestimation of treatment effects, because smaller trials might be methodologically less robust and are 
prone to report larger effect sizes[37, 38]. Therefore, the present meta-analysis may have been underpowered 
to detect a true effect.  
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Table 1: Characteristics of included trials 
Authors
, 
yea
r 
Country Differentia
l 
interventi
ons in 
study 
groups 
Inclusion 
criteria 
Duration 
of 
interventi
on 
Samp
le  
size 
Perce
nt of 
Men 
Mean 
age 
Quali
ty 
A. 
Faursch
ou 
201
4 
Denmark  liraglutide 
vs  
placebo 
plaque 
psoriasis with 
a psoriasis 
area 
and severity 
index (PASI) 
of at least 8, 
(ii) no 
treatment, or 
treatment of 
psoriasis with 
the same 
medication 
for at least 
3 months 
prior to 
inclusion, (iii) 
a steady 
bodyweight 
over a 
3-month 
period with a 
body mass 
index (BMI) 
>25 kg/m2. 
 
8 week 20 ND 48-54 4 
Aaron S 
Kelly 
201
2 
USA Exenatide 
vs  
metformin 
…….. 3 month 50 24% 58.5 ± 
10.0 
2 
G. 
Derosa 
201
0 
Italy Exenatide 
vs 
glibenclam
ide 
poor 
glycemic 
control 
(expressed 
as HbA1c 
level >8.0%) 
and 
overweight 
(body mass 
index [BMI] 
25 and <30 
kg=m2) 
receiving 
therapy with 
metformin at 
the mean 
dosage of 
1,500500mg=
day 
 
12 month 116  >18 
years 
1 
Hui Fan 201
3 
China exenatide 
vs 
metformin 
T2DM 
concomitant 
with NAFLD, 
poor glucose 
control (FBG: 
6.0-10.0 
mmol/L or 
HbA1c: 7-
9%), no acute 
complication
s or 
12 week 117 56.4% 52.35  1 
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severe 
chronic 
complication
s of DM 
 
Jin-dan 
Wu 
201
1 
China Exenatide 
vs  
placebo 
(1) insulin 
injection for 
more than 1 
week 
in the 
previous 3 
months; (2) 
severe 
coronary 
disease 
history in 
the previous 
1 year; (3) 
blood 
creatine 
>133 mmol/L 
for men 
and >106 
mmol/L for 
women; and 
(4) 
glutamate-
pyruvate 
transaminase 
>2.5 times 
greater than 
the normal 
value 
16 week 23 39.1% Exenati
de 
Group; 
57±10 
Placeb
o 
group; 
54±9.5 
3 
MATHIJ
S C. 
BUNCK 
201
0 
Netherla
nds 
exenatide 
vs insulin 
glargine 
ND 12 month 69 ND ND 1 
Ziwen 
Liang 
201
3 
China Exenatide (1) 
obesity (body 
mass index 
[BMI] > 28 
kg/m2) in 
accordance 
with the 
WHO Asia-
Pacific 
classification 
for obesity 
[9]; (2) 
T2DM with 
hypertension 
of 5–10 years 
with 
hypertension 
defined as 
systolic blood 
pressure 
(SBP) >140 
mmHg 
and/or 
diastolic 
(DBP)  >90 
mmHg as per 
1999 
WHO/ISH 
criteria; (3) 
insulin 
therapy in 
combination 
with oral 
12 month 108 64.8% Exenati
de 
Group ; 
50.94 ± 
5.89 
2 
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administratio
n of 
drugs for 12 
months; (4) 
glycated 
hemoglobin 
(HbA1c) > 
7%; (5) age: 
30–60 years; 
(6) 
seronegative 
for 
antibodies 
against 
insulin, islet 
cells and 
glutamic acid 
decarboxylas
e (GAD); (7) 
C-peptide 
level >0.3 
mg/L.  
 
 
